The Collaboration for TB Vaccine Discovery (CTVD) 2nd Annual meeting was held June 23 and 24, 2016 at the Bill & Melinda Gates Foundation Seattle campus. It was a highly collaborative and productive meeting with 107 participants from academia, independent research institutes, industry, funding organizations and the Gates Foundation. Several experts discussed critical advances in the TB vaccine space over the last year and researchers from allied fields (cancer immunology, infectious diseases other than TB) talked about important discoveries relevant for TB vaccine discovery. The different CTVD research communities also shared their outputs for the first year – the DURT (Donor Unrestricted T cells) group has a plan to analyze human DURT response to BCG vaccination, the NHP (non-human primates) group has started working together to standardize the use of PET-CT as an outcome and the WCV (whole cell vaccines) group has a review article (Vaccination Against Tuberculosis with Whole Cell Mycobacterial Vaccines) published in the Journal of Infectious Diseases. CTVD’s aim for the first year was to start small, achieve primary goals (i.e. consolidate membership, launch research communities) and grow. From 20 member institutions in 2015, CTVD now has over 40 members from the US, Europe, Africa, Latin America, and Asia. The CTVD was launched to foster innovation, cooperation and collaboration in the up-stream TB vaccine discovery space. We believe this effort will accelerate development of a more effective vaccine against TB. For more information, please visit the CTVD website www.ctvd.co.